A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care

This publication has 19 references indexed in Scilit:

• The economics of febrile neutropenia: implications for the use of colony-stimulating factors
  European Journal Of Cancer, 1998
• Economie impact of granulopoiesis stimulating agents on the management of febrile neutropenia
  Current Opinion in Oncology, 1998
• Consensus on the use of neutrophil-stimulating hematopoietic growth factors in clinical practice: an international viewpoint
  International Journal of Antimicrobial Agents, 1997
• Filgrastim (r-metHuG-CSF): the first 10 years
  Blood, 1996
• Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology.
  Journal of Clinical Oncology, 1996
• The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy
  European Journal Of Cancer, 1993
• Decision Analysis of Hematopoietic Growth Factor Use in Patients Receiving Cancer Chemotherapy
  JNCI Journal of the National Cancer Institute, 1993
• Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
  European Journal Of Cancer, 1993
• Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
  New England Journal of Medicine, 1991
• Hematopoietic Growth Factors
  New England Journal of Medicine, 1989